Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:1789-1797
Published online before print March 26, 2007, doi: 10.1161/CIRCULATIONAHA.106.660134
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
115/13/1789    most recent
CIRCULATIONAHA.106.660134v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cudmore, M.
Right arrow Articles by Ahmed, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cudmore, M.
Right arrow Articles by Ahmed, A.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CARBON MONOXIDE
Medline Plus Health Information
*High Risk Pregnancy
Related Collections
Right arrow Angiogenesis
Right arrow Cell signalling/signal transduction
Right arrow Endothelium/vascular type/nitric oxide

(Circulation. 2007;115:1789-1797.)
© 2007 American Heart Association, Inc.


Molecular Cardiology

Negative Regulation of Soluble Flt-1 and Soluble Endoglin Release by Heme Oxygenase-1

Melissa Cudmore, PhD; Shakil Ahmad, PhD; Bahjat Al-Ani, PhD; Takeshi Fujisawa, PhD; Heather Coxall, BSc; Kunal Chudasama, BSc; Luke R. Devey, MD; Stephen J. Wigmore, MD; Allyah Abbas; Peter W. Hewett, PhD; Asif Ahmed, PhD

From the Departments of Reproductive and Vascular Biology (M.C., S.A., B.A.-A., T.F., H.C., K.C., A. Abbas, P.W.H., A. Ahmed) and Liver Research Group (L.R.D., S.J.W.), Institute of Biomedical Research, The Medical School, University of Birmingham, and Birmingham Women’s Hospital (M.C., S.A., B.A.-A., T.F., H.C., K.C., A. Abbas, P.W.H., A. Ahmed), Edgbaston, Birmingham, UK.

Correspondence to Dr Asif Ahmed, Department of Reproductive and Vascular Biology, Medical School, University of Birmingham, Edgbaston, Birmingham, West Midlands, B15 2TT, UK. E-mail a.s.ahmed{at}bham.ac.uk

Received August 23, 2006; accepted January 19, 2007.

Background— Preeclampsia is characterized clinically by hypertension and proteinuria. Soluble Flt-1 (sFlt-1; also known as soluble vascular endothelial growth factor receptor-1 [VEGFR-1]) and soluble endoglin (sEng) are elevated in preeclampsia, and their administration to pregnant rats elicits preeclampsia-like symptoms. Heme oxygenase-1 (HO-1) and its metabolite carbon monoxide (CO) exert protective effects against oxidative stimuli. Thus, we hypothesized that HO-1 upregulation may offer protection against preeclampsia by inhibiting sFlt-1 and sEng release.

Methods and Results— Preeclamptic villous explants secreted high levels of sFlt-1 and sEng. Adenoviral overexpression of HO-1 in endothelial cells inhibited VEGF-mediated sFlt-1 release and interferon-{gamma}– and tumor necrosis factor-{alpha}–induced sEng release, whereas HO-1 inhibition potentiated sFlt-1 and sEng production from endothelial cells and placental villous explants. Consistent with these findings, mice lacking HO-1 produced higher levels of sFlt-1 and sEng compared with wild-type mice. Using selective ligands (VEGF-E and placental growth factor) and a receptor-specific inhibitor (SU-1498), we demonstrated that VEGF-induced sFlt-1 release was VEGFR-2 dependent. Furthermore, CO–releasing molecule-2 (CORM-2) or CO decreased sFlt-1 release and inhibited VEGFR-2 phosphorylation. Treatment of endothelial cells with statins upregulated HO-1 and inhibited the release of sFlt-1, whereas vitamins C and E had no effect.

Conclusions— The present study demonstrates that the HO-1/CO pathway inhibits sFlt-1 and sEng release, providing compelling evidence for a protective role of HO-1 in pregnancy, and identifies HO-1 as a novel target for the treatment of preeclampsia.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
PhysiologyHome page
A. Wang, S. Rana, and S. A. Karumanchi
Preeclampsia: The Role of Angiogenic Factors in Its Pathogenesis
Physiology, June 1, 2009; 24(3): 147 - 158.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. Rodriguez, J. F. Alcudia, J. Martinez-Gonzalez, A. Guadall, B. Raposo, S. Sanchez-Gomez, and L. Badimon
Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors
Cardiovasc Res, May 22, 2009; (2009) cvp136v2.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Redecha, N. van Rooijen, D. Torry, and G. Girardi
Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury
Blood, April 23, 2009; 113(17): 4101 - 4109.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Wang, S. Publicover, and Y. Gu
An oxygen-sensitive mechanism in regulation of epithelial sodium channel
PNAS, February 24, 2009; 106(8): 2957 - 2962.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
F. Herse, S. Verlohren, K. Wenzel, J. Pape, D. N. Muller, S. Modrow, G. Wallukat, F. C. Luft, C. W.G. Redman, and R. Dechend
Prevalence of Agonistic Autoantibodies Against the Angiotensin II Type 1 Receptor and Soluble fms-Like Tyrosine Kinase 1 in a Gestational Age-Matched Case Study
Hypertension, February 1, 2009; 53(2): 393 - 398.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. S. Gilbert, S. A.B. Gilbert, M. Arany, and J. P. Granger
Hypertension Produced by Placental Ischemia in Pregnant Rats Is Associated With Increased Soluble Endoglin Expression
Hypertension, February 1, 2009; 53(2): 399 - 403.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
S. M. Engel, T. M. Janevic, C. R. Stein, and D. A. Savitz
Maternal Smoking, Preeclampsia, and Infant Health Outcomes in New York City, 1995-2003
Am. J. Epidemiol., January 1, 2009; 169(1): 33 - 40.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. E. Maynard and R. Thadhani
Pregnancy and the Kidney
J. Am. Soc. Nephrol., January 1, 2009; 20(1): 14 - 22.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
J. Wipff, J. Avouac, D. Borderie, D. Zerkak, H. Lemarechal, A. Kahan, C. Boileau, and Y. Allanore
Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin
Rheumatology, July 1, 2008; 47(7): 972 - 975.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. A. Karumanchi and M. D. Lindheimer
Preeclampsia Pathogenesis: "Triple A Rating"-Autoantibodies and AntiAngiogenic Factors
Hypertension, April 1, 2008; 51(4): 991 - 992.
[Full Text] [PDF]


Home page
HypertensionHome page
C. C. Zhou, S. Ahmad, T. Mi, S. Abbasi, L. Xia, M.-C. Day, S. M. Ramin, A. Ahmed, R. E. Kellems, and Y. Xia
Autoantibody From Women With Preeclampsia Induces Soluble Fms-Like Tyrosine Kinase-1 Production via Angiotensin Type 1 Receptor and Calcineurin/Nuclear Factor of Activated T-Cells Signaling
Hypertension, April 1, 2008; 51(4): 1010 - 1019.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Dulak, J. Deshane, A. Jozkowicz, and A. Agarwal
Heme Oxygenase-1 and Carbon Monoxide in Vascular Pathobiology: Focus on Angiogenesis
Circulation, January 15, 2008; 117(2): 231 - 241.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
Y. Gu, D. F. Lewis, and Y. Wang
Placental Productions and Expressions of Soluble Endoglin, Soluble fms-Like Tyrosine Kinase Receptor-1, and Placental Growth Factor in Normal and Preeclamptic Pregnancies
J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 260 - 266.
[Abstract] [Full Text] [PDF]